Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Active surveillance for prostate cancer: the role of the pathologist.
Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Delahunt B, et al. Among authors: sandler h. Pathology. 2015 Jan;47(1):1-3. doi: 10.1097/PAT.0000000000000186. Pathology. 2015. PMID: 25474525 No abstract available.
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.
Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Carroll PR, et al. Among authors: sandler h. J Urol. 2004 Nov;172(5 Pt 2):S3-5. doi: 10.1097/01.ju.0000142276.19511.ac. J Urol. 2004. PMID: 15535434 Review. No abstract available.
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Kupelian P, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9. doi: 10.1016/j.ijrobp.2004.05.018. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667961
Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.
Zhang M, Ho A, Hammond EH, Suzuki Y, Bermudez RS, Lee RJ, Pilepich M, Shipley WU, Sandler H, Khor LY, Pollack A, Chakravarti A. Zhang M, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1033-42. doi: 10.1016/j.ijrobp.2008.06.1489. Epub 2008 Oct 30. Int J Radiat Oncol Biol Phys. 2009. PMID: 18977097 Free PMC article.
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C. Michalski JM, et al. Among authors: sandler h. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8. doi: 10.1016/j.ijrobp.2009.02.006. Epub 2009 Apr 23. Int J Radiat Oncol Biol Phys. 2010. PMID: 19394158 Free PMC article.
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Thames HD, et al. Among authors: sandler h. Radiother Oncol. 2010 Jul;96(1):6-12. doi: 10.1016/j.radonc.2010.03.020. Epub 2010 Apr 17. Radiother Oncol. 2010. PMID: 20400191
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Mitin T, et al. Among authors: sandler h. Lancet Oncol. 2013 Aug;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. Epub 2013 Jul 1. Lancet Oncol. 2013. PMID: 23823157 Free PMC article. Clinical Trial.
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.
Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME. Amin MB, et al. Among authors: sandler h. Arch Pathol Lab Med. 2014 Oct;138(10):1387-405. doi: 10.5858/arpa.2014-0219-SA. Epub 2014 Aug 5. Arch Pathol Lab Med. 2014. PMID: 25092589 Free article. Review.
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist.
Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB; College of American Pathologists; International Society of Urological Pathology; Association of Directors of Anatomic and Surgical Pathology. Montironi R, et al. Among authors: sandler h. Virchows Arch. 2014 Dec;465(6):623-8. doi: 10.1007/s00428-014-1668-5. Epub 2014 Oct 16. Virchows Arch. 2014. PMID: 25316188
615 results